Magnetic Resonance Spectroscopy in Myocardial Disease

JACC: Cardiovascular Imaging

Volumn 2, Issue 1, 2009, Pages 87-96

  Hudsmith, Lucy E ^a   Neubauer, Stefan ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

31P spectroscopy; adenosine triphosphate; cardiac energetics; high energy phosphates; magnetic resonance spectroscopy; noninvasive metabolic imaging; phosphocreatine

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON 13; CARNITINE; CREATINE; CREATINE KINASE; CREATINE PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LACTIC ACID; PHOSPHORUS 31; PLACEBO; PROTON; SODIUM 23; TAURINE; TRIMETAZIDINE;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC VALUE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MITRAL VALVE REGURGITATION; MYOCARDIAL DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; VALVULAR HEART DISEASE;

ANIMALS; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; ENERGY METABOLISM; HEART DISEASES; HEART FAILURE; HEART TRANSPLANTATION; HEART VALVE DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OBESITY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 58149336904     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.08.005     Document Type: Review

References (65)

1. Ingwall J.S. Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242 (1982) H729-H744
2. Neubauer S. Cardiac Magnetic Resonance Spectroscopy. Established and Emerging Applications (2003), Taylor and Francis Group LLC, London, United Kingdom
3. Bottomley P.A. Noninvasive study of high-energy phosphate metabolism in human heart by depth-resolved 31P NMR spectroscopy. Science 229 (1985) 769-772
4. Bottomley P.A. MR spectroscopy of the human heart: the status and the challenges. Radiology 191 (1994) 593-612
5. Pohmann R., and von Kienlin M. Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 45 (2001) 817-826
6. Bottomley P.A., Atalar E., and Weiss R.G. Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 35 (1996) 664-670
7. Meininger M., Landschutz W., Beer M., et al. Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41 (1999) 657-663
8. Bessman S.P., and Geiger P.J. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 211 (1981) 448-452
9. Lamb H.J., Doornbos J., den Hollander J.A., et al. Reproducibility of human cardiac 31P-NMR spectroscopy. NMR Biomed 9 (1996) 217-227
10. Bottomley P.A., and Weiss R.G. Noninvasive localized MR quantification of creatine kinase metabolites in normal and infarcted canine myocardium. Radiology 219 (2001) 411-418
11. Kreutzer U., Mekhamer Y., Chung Y., and Jue T. Oxygen supply and oxidative phosphorylation limitation in rat myocardium in situ. Am J Physiol Heart Circ Physiol 280 (2001) H2030-H2037
12. Lewandowski E.D., Doumen C., White L.T., LaNoue K.F., Damico L.A., and Yu X. Multiplet structure of 13C NMR signal from glutamate and direct detection of tricarboxylic acid (TCA) cycle intermediates. Magn Reson Med 35 (1996) 149-154
13. Malloy C.R., Jones J.G., Jeffrey F.M., Jessen M.E., and Sherry A.D. Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart. Magma 4 (1996) 35-46
14. Horn M., Weidensteiner C., Scheffer H., Przyklenk K., von Kienlin M., and Neubauer S. Use of 23Na MRS to discriminate viable from non viable tissue: experimental studies. Magma 11 (2000) 42-43
15. Kostler H., Landschutz W., Koeppe S., et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy. Magn Reson Med 56 (2006) 907-911
16. Okada M., Mitsunami K., Inubushi T., and Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS. Magn Reson Med 39 (1998) 772-782
17. Pluim B.M., Lamb H.J., Kayser H.W., et al. Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation 97 (1998) 666-672
18. Lamb H.J., Beyerbacht H.P., van der Laarse A., et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99 (1999) 2261-2267
19. Clarke K., O'Connor A.J., and Willis R.J. Temporal relation between energy metabolism and myocardial function during ischemia and reperfusion. Am J Physiol 253 (1987) H412-H421
20. Weiss R.G., Bottomley P.A., Hardy C.J., and Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 323 (1990) 1593-1600
21. Buchthal S.D., den Hollander J.A., Merz C.N., et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 342 (2000) 829-835
22. Johnson B.D., Shaw L.J., Buchthal S.D., et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109 (2004) 2993-2999
23. Flameng W., Vanhaecke J., Van Belle H., Borgers M., De Beer L., and Minten J. Relation between coronary artery stenosis and myocardial purine metabolism, histology and regional function in humans. J Am Coll Cardiol 9 (1987) 1235-1242
24. von Kienlin M., Rosch C., Le Fur Y., et al. Three-dimensional 31P magnetic resonance spectroscopic imaging of regional high-energy phosphate metabolism in injured rat heart. Magn Reson Med 39 (1998) 731-741
25. Friedrich J., Apstein C.S., and Ingwall J.S. 31P nuclear magnetic resonance spectroscopic imaging of regions of remodeled myocardium in the infarcted rat heart. Circulation 92 (1995) 3527-3538
26. 31P magnetic resonance spectroscopy. Circulation 92 (1995) 15-23
27. Bottomley P.A., and Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 351 (1998) 714-718
28. Horn M., Weidensteiner C., Scheffer H., et al. Detection of myocardial viability based on measurement of sodium content: a (23)Na-NMR study. Magn Reson Med 45 (2001) 756-764
29. Sandstede J.J., Pabst T., Beer M., et al. Assessment of myocardial infarction in humans with (23)Na MR imaging: comparison with cine MR imaging and delayed contrast enhancement. Radiology 221 (2001) 222-228
30. Sandstede J.J., Hillenbrand H., Beer M., et al. Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med 52 (2004) 545-551
31. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
32. Neubauer S., Krahe T., Schindler R., et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86 (1992) 1810-1818
33. 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 16 Suppl O (1995) 115-118
34. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997) 2190-2196
35. Beer M., Seyfarth T., Sandstede J., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40 (2002) 1267-1274
36. Weiss R.G., Gerstenblith G., and Bottomley P.A. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A 102 (2005) 808-813
37. Smith C.S., Bottomley P.A., Schulman S.P., Gerstenblith G., and Weiss R.G. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114 (2006) 1151-1158
38. Nakae I.M.K., Omura T., Yabe T., et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 42 (2003) 1587-1593
39. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006) 942-948
40. Beer M., Wagner D., Myers J., et al. Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy. J Am Coll Cardiol 51 (2008) 1883-1891
41. Fraser Jr. C.D., Chacko V.P., Jacobus W.E., et al. Early phosphorus 31 nuclear magnetic resonance bioenergetic changes potentially predict rejection in heterotopic cardiac allografts. J Heart Transplant 9 (1990) 197-204
42. Bottomley P.A., Weiss R.G., Hardy C.J., and Baumgartner W.A. Myocardial high-energy phosphate metabolism and allograft rejection in patients with heart transplants. Radiology 181 (1991) 67-75
43. Evanochko W.T., Buchthal S.D., den Hollander J.A., et al. Cardiac transplant patients response to the (31)P MRS stress test. J Heart Lung Transplant 21 (2002) 522-529
44. 31P magnetic resonance spectroscopy. Lancet 338 (1991) 973-976
45. Conway M.A., Bottomley P.A., Ouwerkerk R., Radda G.K., and Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 97 (1998) 1716-1723
46. 31P-magnetic resonance spectroscopy. J Investig Med 45 (1997) 453-462
47. Beyerbacht H.P., Lamb H.J., van Der Laarse A., et al. Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219 (2001) 637-643
48. Ashrafian H., Redwood C., Blair E., and Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19 (2003) 263-268
49. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 (2003) 1776-1782
50. Jung W.I., Hoess T., Bunse M., et al. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation 101 (2000) E121
51. Jung W.I., Sieverding L., Breuer J., et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97 (1998) 2536-2542
52. Crilley J.G., Boehm E.A., Rajagopalan B., et al. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 36 (2000) 1953-1958
53. Schocke M.F., Zoller H., Vogel W., et al. Cardiac phosphorus-31 two-dimensional chemical shift imaging in patients with hereditary hemochromatosis. Magn Reson Imaging 22 (2004) 515-521
54. Schocke M.F., Martinek M., Kremser C., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors improve myocardial high-energy phosphate metabolism in men. J Cardiovasc Magn Reson 5 (2003) 595-602
55. Scheuermann-Freestone M., Madsen P.L., Manners D., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107 (2003) 3040-3046
56. Metzler B., Schocke M.F., Steinboeck P., et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson 4 (2002) 493-502
57. McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116 (2007) 1170-1175
58. van der Meer R.W., Hammer S., Smit J.W., et al. Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. Diabetes 56 (2007) 2849-2853
59. Tyler D.J., Hudsmith L.E., Clarke K., Neubauer S., and Robson M.D. A comparison of cardiac (31)P MRS at 1.5 and 3 T. NMR Biomed 21 (2008) 793-798
60. Lee R.F., Giaquinto R., Constantinides C., Souza S., Weiss R.G., and Bottomley P.A. A broadband phased-array system for direct phosphorus and sodium metabolic MRI on a clinical scanner. Magn Reson Med 43 (2000) 269-277
61. Speck O., Scheffler K., and Hennig J. Fast 31P chemical shift imaging using SSFP methods. Magn Reson Med 48 (2002) 633-639
62. Merritt M.E., Harrison C., Storey C., Jeffrey F.M., Sherry A.D., and Malloy C.R. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci U S A 104 (2007) 19773-19777
63. 13C-labelled bicarbonate. Nature 453 (2008) 940-943
64. Neubauer S. Cardiac MR spectroscopy. In: Manning W. (Ed). Atlas of Cardiovascular Magnetic Resonance Imaging (2008), Current Medicine Group, Philadelphia, PA
65. Hudsmith L.E., and Neubauer S. Detection of myocardial disorders by magnetic resonance spectroscopy. Nat Clin Pract Cardiovasc Med 5 Suppl 2 (2008) S49-S56